## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Original): A candesartan cilexetil 1,4-dioxane solvate.

2. (Previously Presented): The candesartan cilexetil 1,4-dioxane solvate of claim 1, wherein the content of 1,4-dioxane is 8.8 to 13.0 % w/w.

3. (Previously Presented): The candesartan cilexetil 1,4-dioxane solvate of claim 1, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.0, 10.7, 16.2, 18.0, 19.7, 20.6, 21.3, 21.7, and 22.3 degrees.

4. (Original): Candesartan cilexetil 1,4-dioxane solvate of claim 3, further characterized by an x-ray powder diffraction pattern as in figure 1.

5. (Previously Presented): The process for the preparation of candesartan cilexetil 1,4-dioxane solvate of claim 1, which comprises:

a) dissolving candesartan cilexetil in 1,4-dioxane; and

b) crystallizing candesartan cilexetil as 1,4-dioxane solvate from the solution at 5°C to 15°C.

6. (Currently Amended): The process according to claim 5, wherein candesartan cilexetil used is a crystalline ~~or amorphous~~ form of candesartan cilexetil.

7. (Previously Presented): The process according to claim 6, wherein the crystalline form of candesartan cilexetil is candesartan cilexetil form III.

8. (Original): A crystalline candesartan cilexetil form III, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.3, 7.3, 8.1, 8.9, 10.1, 14.6, 15.0, 15.8, and 18.8 degrees.

9. (Original): Candesartan cilexetil form III of claim 8, further characterized by an x-ray powder diffraction pattern as in figure 2.

10. (Previously Presented): The process for the preparation of candesartan cilexetil form III of claim 8, which comprises:

a) mixing candesartan cilexetil with toluene;
b) heating to obtain clear solution;
c) cooling slowly to 0°C to 5°C in about 1 hour;
d) maintaining at 0°C to 5°C for about 1 hour; and
e) filtering the separated solid.

11. (Previously Presented): The process according to claim 10, wherein candesartan cilexetil used is candesartan cilexetil as 1,4-dioxane solvate of claim 1.

12. (Withdrawn): A crystalline candesartan cilexetil form IV, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.1, 7.1, 11.6, 11.9, 17.9, 19.8 and 21.2 degrees.

13. (Withdrawn): Candesartan cilexetil form IV of claim 12, further characterized by an x-ray powder diffraction pattern as in figure 3.

14. (Withdrawn): The process for the preparation of candesartan cilexetil form IV of claim 12, which comprises:

a) heating the mixture of candesartan cilexetil, methyl tert-butyl ether and methanol to 50°C to 55°C;
b) cooling to 20°C to 25°C;
c) maintaining at 20°C to 25°C for about 10 hours; and
d) separated crystals are collected by filtration.

15. (Withdrawn): The process according to claim 14, wherein candesartan cilexetil used is a crystalline or amorphous or dioxane solvated form of candesartan cilexetil.

16. (Withdrawn): The process according to claim 15, wherein candesartan cilexetil used is candesartan cilexetil 1,4-dioxane solvate of claim 1.

17. (Withdrawn): The process according to claim 15, wherein candesartan cilexetil used is candesartan cilexetil form III of claim 8.

18. (Withdrawn): A pharmaceutical composition comprising candesartan cilexetil form III of claim 8 or candesartan cilexetil form IV of claim 12 and a pharmaceutically acceptable carrier.

19. (Currently Amended): A solid pharmaceutical composition comprising candesartan cilexetil form III in stable crystalline form.

20. (Withdrawn): The pharmaceutical composition of claim 18, wherein candesartan cilexetil form IV is used.